Evaluation of different beta-counting systems involved in Y-Zevalin quality control

Nuclear Medicine Communications

Volumn 28, Issue 12, 2007, Pages 943-950

  Urbano, Nicoletta ^a   Modoni, Sergio ^a  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

Author keywords

Beta radiation detection; Quality control; Yttrium 90; Zevalin

Indexed keywords

IBRITUMOMAB TIUXETAN;

ARTICLE; AUTORADIOGRAPHY; BETA RADIATION; CALIBRATOR; DIAGNOSTIC ACCURACY; DOSIMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; LABORATORY TEST; LIQUID SCINTILLATION COUNTING; QUALITY CONTROL; RADIATION DETECTION; RADIATION DOSE; RADIOACTIVITY; RADIODIAGNOSTIC EQUIPMENT AND SUPPLIES; SENSITIVITY ANALYSIS; THIN LAYER CHROMATOGRAPHY;

ANTIBODIES, MONOCLONAL; BETA RAYS; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; ISOTOPE LABELING; ITALY; QUALITY ASSURANCE, HEALTH CARE; RADIOMETRY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 37349047823     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3282f1ac59     Document Type: Article

References (18)

1. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453-2463.
2. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:3262-3269.
3. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 7:3793-3803.
4. Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99:4336-4342.
5. 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma. Semin Oncol 2003; 30(6, suppl 17):11-16.
6. 90Y) ibritumomab tiuxetan (Zevalin®) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2005; 20:185-188.
7. Emmanouilides C, Witzig TE, Gordon LI, Vo K, Wiseman GA, Flinn IW, et al. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2006; 47:629-636.
8. 90Y-labeled anti-CD20 monoclonal antibody conjugated to MX-DTPA, a high-affinity chelator for yttrium Abstract. Proc Am Assoc Clin Res 1999; 40:574.
9. Hnatowich DJ, Virzi R, Doherty PW. DTPA-coupled antibodies labelled with yttrium-90. J Nucl Med 1985; 26:503-509.
10. 88Y compounds (Author's translation). Nuklearmedizin 1981; 20:35-39.
11. MacDonald NS, Nusbaum RE, Alexander GV, Ezmirlian F, Spain P, Rounds DE. The skeletal deposition of yttrium. J Biol Chem 1952; 195:837-841.
12. 3+. Nucl Med Biol 2004; 31:821-824.
13. 90Y-Ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma. Semin Oncol 2005; 32(S1):S44-S49.
14. Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003; 21:1263-1270.
15. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 2003; 44:465-474.
16. Schilder R, Molina A, Bartlett N, Witzig T, Gordon L, Murray J, et al. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm 2004; 19:478-481.
17. 90Y-Zevalin thin-layer chromatography plates. Nucl Med Commun 2005; 28:163-166.
18. Decristoforo C, Zaknun J, Kohler B, Oberladstaetter M, Riccabona G. The use of electronic autoradiography in radiopharmacy. Nucl Med Biol 1997; 24:361-365.